Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

20112,368 citationsJournal Articlebronze Open Access

Authors

Robert A. Burger · Fox Chase Cancer Center

Mark F. Brady · Roswell Park Comprehensive Cancer Center

Michael A. Bookman

Gini F. Fleming · University of Chicago

Bradley J. Monk · St. Joseph's Hospital and Medical Center

Helen Huang · Gynecologic Oncology Group

Robert S. Mannel · University of Oklahoma Health Sciences Center

Abstract

The use of bevacizumab during and up to 10 months after carboplatin and paclitaxel chemotherapy prolongs the median progression-free survival by about 4 months in patients with advanced epithelial ovarian cancer. (Funded by the National Cancer Institute and Genentech; ClinicalTrials.gov number, NCT00262847.).

Topics & Keywords

Ovarian cancer diagnosis and treatment Angiogenesis and VEGF in Cancer Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 365, Issue 26, pp. 2473-2483

DOI: 10.1056/nejmoa1104390

Field-Weighted Citation Impact: 152.88